Jefferies assumed coverage of Roche (RHHBY) with an Underperform rating and CHF 230 price target The stock is “expensive,” but with meaningful risk to the downside to a number of franchises, most importantly Vabysmo, the analyst tells investors. The firm voices concerns about several competitor read-outs in the next 12 months that could expose risk to drugs as well.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Rapt Therapeutics initiated with a Buy at Guggenheim
- Labcorp to offer Elecsys pTau181 test for Alzheimer’s disease
- Roche reports 9 month group sales CHF 45.86B vs CHF 44.984B last year
- Roche sees FY25 core EPS growing in high single digit range
- Trump Trade: Trump administration prepares new probe into pharma prices